Meningococcal Infection Clinical Trial
Official title:
Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to Monovalent Hib Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.
The booster phase of the study will evaluate the safety of Hib-MenCY-TT vaccine compared to
a control group receiving licensed Hib conjugate vaccine at 12 to 15 months of age.
This protocol posting deals with objectives & outcome measures of the booster phase. The
objectives & outcome measures of the primary phase are presented in a separate protocol
posting (NCT number = NCT00345579).
No new recruitment will take place during this booster phase of the study. The Protocol
Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Hib-MenCY-TT = GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis
serogroups C and Y-tetanus toxoid conjugate vaccine.
The study will be conducted in a single blind manner up to 30 days after administration of
the booster dose; the extended safety follow-up after the booster dose will be conducted in
an unblinded manner.
All subjects will receive Prevnar, M-M-R II and Varivax as study vaccines, preferencially
co-administered with the booster dose of Hib-MenCY-TT/PedvaxHIB.
Note: This protocol posting deals with the objectives & outcome measures for the booster
phase of the study. The objectives & outcome measures for the primary phase are presented in
a separate protocol posting (NCT00345579)
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
| Completed |
NCT01543087 -
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
|
Phase 3 | |
| Completed |
NCT01442675 -
Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine
|
Phase 2 | |
| Completed |
NCT00359983 -
Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB
|
Phase 3 | |
| Recruiting |
NCT06128733 -
Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
|
Phase 1/Phase 2 | |
| Completed |
NCT00715234 -
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
|
N/A | |
| Completed |
NCT01359449 -
Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations
|
Phase 3 | |
| Recruiting |
NCT04843111 -
Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)
|
||
| Completed |
NCT01890759 -
Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation
|
Phase 3 | |
| Completed |
NCT01086969 -
A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India
|
Phase 3 | |
| Completed |
NCT00700635 -
Dose Comparison Study of Menactra® in US Children
|
Phase 2 | |
| Completed |
NCT00310635 -
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
|
Phase 4 | |
| Completed |
NCT01659996 -
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
|
Phase 4 | |
| Completed |
NCT01340898 -
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers
|
Phase 3 | |
| Completed |
NCT00392808 -
Immunogenicity of the Booster Dose of Two MenC Vaccines
|
Phase 4 | |
| Completed |
NCT00258856 -
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
|
Phase 2 | |
| Completed |
NCT00806195 -
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
|
Phase 3 | |
| Completed |
NCT00269477 -
Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®
|
Phase 2 | |
| Completed |
NCT00643916 -
Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age
|
Phase 2 | |
| Completed |
NCT01049035 -
A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
|
Phase 2 |